Blue Ocean Clinical Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$38,031	32
2024	Research	$77,170	49
2023	Research	$196,358	44
2022	Research	$186,314	38
2019	Research	$4,500	1

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $359,174 117 payments
Alexion Pharmaceuticals, Inc. $59,472 3 payments
Ocular Therapeutix, Inc. $44,269 9 payments
Apellis Pharmaceuticals, Inc. $34,958 34 payments
Mallinckrodt Enterprises LLC $4,500 1 payment

Studies the money was for Research payments · program years 2019–2025

Faricimab for Under Represented Patients With Dme $216,090 84 payments
A Phase 1 Sad MD in Diabetic MacUlar Edema $142,874 31 payments
A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) $59,472 3 payments
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $44,269 9 payments
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD $34,958 34 payments
A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, Or Panuveitis $4,500 1 payment
PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $210 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.